Lung cancer is the leading cause of cancer-related death. The most frequent forms of treatment for lung cancer include chemotherapy, radiotherapy, and surgery. The most common type of lung cancer is non small cell lung cancer (NSCLC) which contributes to around85% of total cases of lung cancer. In NSCLC, the most frequent subtype reported is squamouscell carcinoma of the lung. Non -small cell lung cancer can be divided into stages based on the spread of the disease to the adjacent lymph nodes. Patients with stage III NSCLC are quite diverse and frequently require individualized care. Due to the high prevalence of local recurrence and distant metastases, surgery is often the only treatment option indicated for these stage III patients. Neoadjuvant therapy (NAT), can extend the survival of lung cancer patients with resection, by decreasing tumor activity. In this therapy, chemotherapy or radiotherapy is administered to the patient before proceeding withsurgery. This NAT has the ability to modify lung cancer patients from potentially treatable to treatable stage. According to the literature, albumin-bound paclitaxel (ab-P), a new solvent-free nanomedicine of taxane, demonstrates low toxicity to normal tissues and has a favorable tumor-specific killing effect. It is advised as the first-line treatment for LSCC patients and has excellent anti-tumor activity. Therefore, ab-P + platinum as NAT may be a viable treatment for stage IIIA and IIIB potentially resectable LSCC.The response of patients with potentially resectable LSCC to neoadjuvant ab-P plus carboplatin (carboplatin - platinum containing drug) is yet uncertain due to the limited number of studies on this form of NAT. In this research article, a retrospective analysis was conducted in order to assess the effectiveness and safety of nab-PC in patients with locally advanced but potentially treatable LSCC. Methodology: 1. Patients were taken fromthe Human Cancer Hospital between December 2017 and December 2019 who had been diagnosed with LSCC. 2. The inclusion criteria was that the patient should be under 18 years of age,LSCC should be potentially resectable (stage IIIA-IIIB patients with more than one involved mediastinal lymph node, or large masses with suspected infiltration of vital organs which are difficult to resect)and they should have taken two-cycle ab-P plus platinum as pre-operative treatment. 3. For a 21-day cycle, patients were given nab-P (100 mg/m2 on days 1, 8, and 15) and carboplatin (6 mg/mL/min on day 1). For evaluation : 1. TNS staging was done according to the Lung Cancer Stage Classification definition. 2. Within 21 days of the two NAT cycles, transforming tumors were evaluated using computed tomography (CT) in accordance with the RECIST(response evaluation criteria of solid tumors) criteria and adverse effects were recorded using the CTCAE criteria (common terminology criteria for adverse events). 3. The percentage of patients who have transformed from potentially resectable to resectable was used to calculate the surgery conversion rate (SCR), and the total percentage of patients who had a complete response (CR) or partial response (PR) was used to compute the overall response rate (ORR) and disease control rate (DCR). 4. A multidisciplinary team should be involved in the treatment plan. Following surgery, the tumors were representatively sampled using 1 slice per centimetre of tumor diameter, and were examined under light microscopy by two pathologists to ascertain the extent of the treatment to make a histopathological diagnosis and gauge the treatment's overall impact, including any necrosis, fibrosis, and inflammation. Major pathological response (mPR) was defined as less than 10% residual viable tumor, whereas pathological CR (pCR) was defined as the absence of any viable tumor cells. Results: 1. Using SPSS version 22, the statistical analyses were carried out. The significance level was set at 0.05 for all analyses, and the P values were calculated. 2. Retrospective screening was performed on a total of 486 lung cancer treated patients with stages IIIA-IIIB LSCC. 3. They excluded 437 patients who had tumors that were at first thought to be resectable (n = 132) or unresectable (n = 305). This retrospective cohort research includes 49 patients as a result. 4. Evaluations of the therapy response were permissible for all 49 patients. 33 of the 49 patients recorded a partial response, but no patient showed complete response. (ORR = 67%). 5. After two cycles of NAT, all these 33 (67%) individuals were deemed eligible for surgery, but 2 patients declined surgery due to their personal reasons. In the end, 31 patients underwent surgery. 6. In 31 patients type of surgeries conducted are as follows : Baseed on the equipment used: (a) 21 - thoracotomy (b) 10 - video-assisted thoracoscopic surgery Based on the method of approach : (c) 23 - lobectomy (d) 08 - pneumonectomy 7. In 23 patients, the staging of tumor has decreased from: (a) N2 to N0 in 8 patients (b) N2 to N1 in 9 patients (c) N1 to N0 in 6 patients 8. In the 31 patients who underwent surgery, 11 (35%) had a mPR( less than 10% residual tumor after neoadjuvant therapy) and among them, 5 patients acheived a pathologic complete response (PCR). 9. The ORR for the patients who attained a mPR was 82%. The radiographic objective response and mPR of the patients who underwent resection did not correlate (correlation coefficient = 0.54; P 0.05). And neither gender, histology type, stage, nor past smoking history were factors in the pathology response. Impact of research: 1. This study demonstrated that nab-PC has promising anti-tumor effectiveness and acceptable tolerability, making it a viable neoadjuvant regimen choice for LSCC patients who were amenable to surgery. 2. Additionally, it also revealed that ab-PC combined with immunotherapy may be a viable NAT for individuals with LSCC who may be candidates for surgicalresection.